SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $26.78 per share for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2016-02-25
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2014-09-30 was $21.19, a 2.76% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2014-06-30 was $23.11, a 145.07% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2014-03-31 was $30.26, a 104.05% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2013-09-30 was $20.62.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2015 was $26.78, a 17.51% increase from fiscal 2014.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2014 was $22.79, a 35.41% increase from fiscal 2013.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2013 was $16.83, a 33.68% increase from fiscal 2012.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2012 was $12.59, a 27.17% increase from fiscal 2011.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2015-12-31 | $26.78 10-K · filed 2016-02-25 | |||
| 2014-12-31 | $22.79 10-K · filed 2016-02-25 | |||
| 2014-09-30 | $21.19 10-Q · filed 2014-11-06 | $22.63 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | $23.11 10-Q · filed 2014-08-07 | $25.13 10-Q · filed 2014-08-07 | ||
| 2014-03-31 | $30.26 10-Q · filed 2014-05-08 | |||
| 2013-12-31 | $16.83 10-K · filed 2016-02-25 | |||
| 2013-09-30 | $20.62 10-Q · filed 2014-11-06 | $11.51 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $9.43 10-Q · filed 2014-08-07 | $9.60 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $14.83 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | $12.59 10-K · filed 2015-02-26 | |||
| 2012-09-30 | $11.32 10-Q · filed 2012-11-07 | |||
| 2012-06-30 | $10.16 10-Q · filed 2012-08-07 | |||
| 2011-12-31 | $9.90 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $26.52 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |